Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations

References

• Aithal GP, Day CP, KesteVen PJ, Daly AK. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719.
   PubMed Web of Science ®Google Scholar
• Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, Nacak M, Roots I. 1999. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48:409–415.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:262–265.
   Web of Science ®Google Scholar
• Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH. 2011. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 72:442–450.
   PubMed Web of Science ®Google Scholar
• Botton MR, Prolla Viola P, Bandinelli E, Leiria T, Rohde L, Hutz MH. 2013. A new algorithm for weekly phenprocoumon dose variation in a Southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. Basic Clin Pharmacol Toxicol 114:323–329.
   PubMed Web of Science ®Google Scholar
• Bravo-Villalta H, Yamamoto K, Nakamura K, Baya´ A, Okada Y, Horiuchi R. 2005. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian Population: and investigative and comparative study. Europ J Clin Pharmacol 61:179–184.
   PubMed Web of Science ®Google Scholar
• Castelán-Martínez OD, Hoyo-Vadillo C, Sandoval-García E, Sandoval-Ramírez L, González-Ibarra M, Solano-Solano G, Gomez-Diaz R, Parra E, Cruz M, Valladares-Salgado A. 2013. Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populations. Gene 523:167–172.
   PubMed Web of Science ®Google Scholar
• Castro de Guerra D, Flores S, Izaguirre MH. 2013. Distribution of CYP2C19*2 and CYP2C19*3 polymorphisms in Venezuelan populations with different admixture. Ann Hum Biol 40:197–200.
   PubMed Web of Science ®Google Scholar
• Castro de Guerra D, Izaguirre MH, Figuera Pérez C, Arroyo Barahona E, Rodríguez Larralde A, VíVenes de Lugo M. 2011. Gender differences in ancestral contribution and admixture in Venezuelan populations. Hum Biol 83:345–361.
   PubMed Web of Science ®Google Scholar
• Clarke K, Warwick R. 2001. Change in marine communities: an approach to statistical analysis and interpretation. 2nd ed. Plymouth, UK: Plymouth Marine laboratory.
   Google Scholar
• Chiurillo M. 2014. Genomic biomarkers related to drug response in Venezuelan populations. Drug Metab Drug Interact 30:1–9.
   Google Scholar
• Esperón P, Raggio V, Goyeneche BCL, Lorenzo M, Taub I, Stoll M. 2008. Genotipo de los genes VKORC1 y CYP2C9 en la respuesta individual a la warfarina. Rev Med Urug 24:267–277.
   Google Scholar
• Excoffier L, Laval G, Schneider S. 2005. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 1:47–50.
   PubMed Web of Science ®Google Scholar
• Flores Gutiérrez S, Castro de Guerra D, Izaguirre MH, VíVenes de Lugo M. 2015. Distribución y frecuencia de polimorfismos en el gen CYP2C19 en diferentes poblaciones Venezolanas. Investigación Clínica 56 (Suppl 1):821–825.
   Google Scholar
• García-Martín E, Martínez C, Ladero JM, Agúndez JA. 2006. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10:29–40.
   PubMed Web of Science ®Google Scholar
• Heinen D, García-Castro A. 2000. The multiethnic network of the Lower Orinoco in early colonial times. Ethnohistory 47:561–579.
   Web of Science ®Google Scholar
• Isaza C, Beltrán L, Henao J, Porras G, Pinzón A, Vallejos Á, Machado J. 2010. Factores genéticos y ambientales asociados con la respuesta a warfarina en pacientes colombianos. Biomédica 30:410–420.
   PubMed Web of Science ®Google Scholar
• Ishizaki T. 2002. CYP2 Pharmacogenetics and tailor-made therapeutic implications. Int Congress Series 1244:1–9.
   Google Scholar
• Kesavan R, Narayan S, Adithan C. 2010. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin- induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 66:689–696.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Brockmöller J. 2005. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1–16.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Tsahuridu MWJ, Roots I, Brockmöller J. 2004. The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Med 1:63–84.
   PubMedGoogle Scholar
• Krajciova L, Petrovic R, Deziova L, Chandoga J, Turcani P. 2014. Frequency of selected single nucleotide polymorphisms influencing the warfarin pharmacogenetics in Slovak population. Eur J Haematol 93:320–328.
   PubMed Web of Science ®Google Scholar
• Lee C, Goldstein J, Pieper J. 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–263.
   PubMedGoogle Scholar
• Miners JO, Birkett DJ. 1998. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538.
   PubMed Web of Science ®Google Scholar
• Nei M. 1973. Analysis of gene diversity in subdivided populations. Proc Natl Acad Sci USA 70:3321–3323.
   PubMed Web of Science ®Google Scholar
• Nelson D, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, et al. 1996. P450 superfamily: update on new sequences, gene mapping, accession number and nomenclature. Pharmacogenetics 6:1–42.
   PubMedGoogle Scholar
• Ota T. 1993. DISPAN: genetic distance and phylogenetic analysis. University Park, Pennsylvania State University, PA: Institute of Molecular Evolutionary Genetics, Pennsylvania State University.
   Google Scholar
• Pimenoff VN, Laval G, Comas D, Palo JU, Gut I, Cann H, Excoffier L, Sajantila A. 2012. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates. Pharmacogenet Genomics 22:846–857.
   PubMed Web of Science ®Google Scholar
• Rettie AE, Haining RL, Bajpai M, Levy RH. 1999. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 35:253–255.
   PubMed Web of Science ®Google Scholar
• Roco A, Quinones L, Agundez JA, Garcia-Martin E, Squicciarini V, Miranda C, Garay J, et al. 2012. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations. Front Gene 3:229.
   PubMedGoogle Scholar
• Rodríguez Larralde A, Castro de Guerra D. 2012. Inferencia de movimientos migratorios en los estados del oriente de Venezuela, realizada en base a la distribución de apellidos. Interciencia 37:349–354.
   Google Scholar
• Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. 2010. World allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 55:582–589.
   PubMed Web of Science ®Google Scholar
• Salzano F. 2002. Molecular variability in Amerindians: widespread but uneven information. Ann Academ Brasil Cien 74:223–263.
   PubMed Web of Science ®Google Scholar
• Seven M, Batar B, Unal S, Yesil G, Yuksel S, Guven M. 2013. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19 and CYP2D6 on drug resistant epilepsy in Turkish children. Mol Diagn Ther 18:229–236.
   Web of Science ®Google Scholar
• Sosa-Macías M, Lazalde-Ramos BP, Galaviz-Hernández C, Rangel-Villalobos H, Salazar-Flores J, Martínez-Sevilla VM, Martínez-Fierro ML, et al. 2013. Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. Pharmacogenomics J 13:567–572.
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G, Genro JP, de Moraes MO, Ojopi EB, Pena SD, Perini JA, Ribeiro Dos Santos A, Romano-Silva MA, Santana I, Struchiner CJ. 2012. Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 12:267–276.
   PubMed Web of Science ®Google Scholar
• Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. 1996. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341–349.
   PubMedGoogle Scholar
• The International HapMap Consortium. 2003. The International HapMap Project. Nature 426:789–796.
   PubMed Web of Science ®Google Scholar
• Vargens D, Petzl-Erler M, Suarez-Kurtz G. 2012. Distribution of CYP2C polymorphisms in a Ameridian population of Brazil. Basic Clin Pharmacol Toxicol 110:396–400.
   PubMed Web of Science ®Google Scholar
• Vicente J, González-Andrade F, Soriano A, Fanlo A, Martínez-Jarreta B, Sinués B. 2014. Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study. Mol Biol Reps 41:1267–1272.
   PubMed Web of Science ®Google Scholar
• Vormfelde SV, Schirmer M, Toliat MR, Meineke I, Kirchheiner J, Nürnberg P, Brockmöller J. 2007. Genetic variation at the CYP2C locus and its association with torsemide biotransformation. Pharmacogenomics J 7:200–211.
   PubMed Web of Science ®Google Scholar
• Walton R, Kimber M, Rockett K, Trafford C, Kwiatkowski D, Sirugo G. 2005. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat Genet 37:915–916.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. 2005. Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221.
   PubMed Web of Science ®Google Scholar
• Zanger U, Turpeinen M, Klein K, Schwab M, 2008. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–1108.
   PubMed Web of Science ®Google Scholar